000			02303 a2200589 4500
005			20250515131718.0
264		0	_c20090323
008			200903s 0 0 eng d
022			_a1573-7241
024	7		_a10.1007/s10557-008-6129-4 _2doi
040			_aNLM _beng _cNLM
100	1		_aWang, Zhi
245	0	0	_aGinsenoside Rb1 preconditioning protects against myocardial infarction after regional ischemia and reperfusion by activation of phosphatidylinositol-3-kinase signal transduction. _h[electronic resource]
260			_bCardiovascular drugs and therapy _cDec 2008
300			_a443-52 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAndrostadienes _xpharmacology
650	0	4	_aAnimals
650	0	4	_aBlood Pressure _xdrug effects
650	0	4	_aBlotting, Western _xmethods
650	0	4	_aCreatine Kinase _xantagonists & inhibitors
650	0	4	_aCreatine Kinase, MB Form _xantagonists & inhibitors
650	0	4	_aDimethyl Sulfoxide _xadministration & dosage
650	0	4	_aDrug Administration Schedule
650	0	4	_aDrug Therapy, Combination
650	0	4	_aGinsenosides _xantagonists & inhibitors
650	0	4	_aHeart Rate _xdrug effects
650	0	4	_aInjections, Intravenous
650	0	4	_aIschemic Preconditioning, Myocardial _xmethods
650	0	4	_aL-Lactate Dehydrogenase _xantagonists & inhibitors
650	0	4	_aMale
650	0	4	_aMolecular Structure
650	0	4	_aMyocardial Infarction _xcomplications
650	0	4	_aMyocardial Reperfusion Injury _xcomplications
650	0	4	_aPanax _xchemistry
650	0	4	_aPharmaceutical Vehicles _xchemistry
650	0	4	_aPhosphatidylinositol 3-Kinases _xmetabolism
650	0	4	_aPhosphorylation _xdrug effects
650	0	4	_aPlacebos _xadministration & dosage
650	0	4	_aRats
650	0	4	_aRats, Sprague-Dawley
650	0	4	_aSignal Transduction _xdrug effects
650	0	4	_aTetrazolium Salts
650	0	4	_aTroponin T _xantagonists & inhibitors
650	0	4	_aWortmannin
700	1		_aLi, Min
700	1		_aWu, Wei-kang
700	1		_aTan, Hong-mei
700	1		_aGeng, Deng-feng
773	0		_tCardiovascular drugs and therapy _gvol. 22 _gno. 6 _gp. 443-52
856	4	0	_uhttps://doi.org/10.1007/s10557-008-6129-4 _zAvailable from publisher's website
999			_c18154700 _d18154700